TocopheRx will be presenting results demonstrating the efficacy and safety of TOP001 on mouse oocytes at ESHRE 2016 in Helsinki, Finland on 06-July. These results, demonstrate that oocytes collected from TOP001-treated mice develop into viable embryos at the same rate as mice treated with recombinant FSH.
TocopheRx presented recent findings on safety and toxicology of its FSHR allosteric agonists at the Society for Reproductive Investigation (SRI) in Montreal, Canada, March 16-19, 2016. TOP001 has demonstrated a wide safety margin between doses that stimulate ovarian follicular growth in animal models and highest doses tested in toxicology models (rat and dog, no off-target effects).
TocopheRx will be present at JP Morgan in San Francisco Jan 11-12, 2016
Discovery and development of small molecule allosteric modulators of glycoprotein hormone receptors, Nataraja SG., Yu HN. & Palmer SS. Front. Endocrinol., 2015. 6, 142
Investigation of a thiazolidinone derivative as an allosteric modulator of follicle stimulating hormone receptor: evidence for its ability to support follicular development and ovulation, Sriraman V, Denis D, de Matos D, Yu H, Palmer S, Nataraja S. Biochem Pharmacol. 2014 May 15;89(2):266-75.
Discovery of substituted benzamides as follicle stimulating hormone receptor allosteric modulators, Yu HN, Richardson TE, Nataraja S, Fischer DJ, Sriraman V, Jiang X, Bharathi P, Foglesong RJ, Haxell TF, Heasley BH, Jenks M, Li J, Dugas MS, Collis R, Tian H, Palmer S, Goutopoulos A. Bioorg med Chem Lett. 2014 May 1, 24(9): 2168-72